NCT00956202已完成2 期
Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-Origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Subjects Aged 3 to 17 Years
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 303
- 试验地点
- 15
- 主要终点
- Safety: To provide information concerning the safety (in terms of solicited injection site and systemic reactions and unsolicited adverse events) of Swine A/H1N1 influenza vaccines.
研究概览
简要总结
The purpose of this study is to generate data on immunogenicity and safety of the monovalent H1N1 vaccine in support of the development and registration.
Primary objectives:
- To describe the immune response to vaccines 21 days after each vaccination in all participants.
- To describe the antibody persistence eight months after the first vaccine administration using HAI method, in a subset of participants who received two injections.
- To describe the immune response against the A/H1N1 strain using HAI method 21 days after a vaccination with the 2010-2011 NH seasonal TIV administered approximately 13 months after the first vaccination in the subset of participants who received two injections.
- To describe the safety profile of each vaccine in all participants.
详细描述
All participants will receive two injections of their randomized vaccine on Day 0 and Day 21, respectively.
A subset of children and adolescents participants eligible for the antibody persistence evaluation were sampled 8 months after the first vaccination, they will also be proposed to receive the 2010-2011 Northern Hemisphere (NH) seasonal Trivalent Influenza Vaccine (TIV) 13 months after the first vaccination. Immunogenicity response will be evaluated before vaccination and 21 days after vaccination with TIV, respectively.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 3 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- •All subjects:
- •Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination
- •Planned participation in another clinical trial during the present trial period
- •Receipt of any vaccine in the 4 weeks preceding the trial vaccinations
- •Planned receipt of any vaccine prior to the Day 42 blood sample
- •Receipt of blood or blood-derived products in the past 3 months which might interfere with the assessment of immune response
- •Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- •Seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B antigen, or Hepatitis C as reported by parents/legal representative
- •Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances
- •Thrombocytopenia contraindicating intramuscular (IM) vaccination as reported by parents/legal representative
- •Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion contraindicating IM vaccination
- •Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
- •Chronic illness that in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion
- •Employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members of the employees or the Investigator
- •Previous participation in a trial investigating a vaccine with the swine-origin A/H1N1 influenza strain
- •Confirmed infection with the swine-origin A/H1N1 influenza strain (different from the seasonal strain) in 2009
- •Febrile illness (temperature ≥38.0°C) or moderate or severe acute illness/infection on the day of vaccination, according to Investigator judgment
- •Receipt of any allergy shots and/or seasonal allergy medication in the 7-day period prior to enrollment (vaccination), or scheduled to receive any allergy shots and/or seasonal allergy medication in the 7-day period after enrollment (vaccination)
- •Subjects aged 12 to 17 years:
- •Known pregnancy, or a positive urine pregnancy test
- •Currently breastfeeding a child
- •Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures
- •At Visit 05 (Month 8), for antibody persistence assessment:
- •Subjects who received, in the context of a pandemic immunization program, another A/H1N1 pandemic influenza vaccine than the Investigational Medicinal Products.
结局指标
主要结局
Safety: To provide information concerning the safety (in terms of solicited injection site and systemic reactions and unsolicited adverse events) of Swine A/H1N1 influenza vaccines.
时间窗: 0-7 days post-vaccination and entire study duration
Immunogenicity: To provide information concerning the immunogenicity of Swine A/H1N1 influenza vaccines
时间窗: 21 days post vaccination
次要结局
未报告次要终点
研究者
研究点 (15)
Loading locations...
相似试验
已完成
2 期
A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 MonthsSwine-origin A/H1N1 InfluenzaInfluenzaNCT00956046Sanofi Pasteur, a Sanofi Company401
已完成
2 期
A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the ElderlySwine-origin A/H1N1 InfluenzaInfluenzaNCT00954798Sanofi Pasteur, a Sanofi Company450
已完成
2 期
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 YearsSwine-origin A/H1N1 InfluenzaInfluenzaNCT00952419Sanofi Pasteur, a Sanofi Company474
已完成
2 期
A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the ElderlySwine-origin A/H1N1 InfluenzaInfluenzaNCT00952276Sanofi548
已完成
2 期
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the ElderlySwine-origin A/H1N1 InfluenzaInfluenzaNCT00953524Sanofi Pasteur, a Sanofi Company849